Shanghai World Leader Pharmaceutical

Shanghai World Leader Pharmaceutical Co., Ltd. (also known as Shanghai Shiling Pharmaceutical) is a China-based biotechnology company specializing in innovative drug delivery systems. Founded in 2018, the company focuses on developing mucosal and transdermal delivery platforms to create improved versions of existing therapeutics with enhanced patient compliance and efficacy. Its lead candidate is a semaglutide nasal spray, currently in Phase 1 clinical trials for the treatment of obesity and overweight conditions, aimed at providing a cost-effective and non-invasive alternative to injectable GLP-1 therapies. The company is also advancing a transdermal patch for rasagiline mesylate to treat Parkinson's disease. Shanghai World Leader Pharmaceutical maintains strategic R&D collaborations with partners like Proya Cosmetics and holds patents across multiple global markets.